Riskpilot← Back to searchSign inGet full accessBiogen Finland Oy
OYActiveY-tunnus 1538877-3Bertel Jungin Aukio 5-CWholesale of pharmaceutical and medical goods · NACE 4646Est. 199912 employees
Revenue 2024
EUR 19M
+3% vs 2023
EBITDA margin
3.7%
Equity ratio
—
Financial strength
Net profit 2024
EUR 558K
12 employees
| Revenue | EUR 19M | +3% |
| EBITDA | EUR 703K | — |
| Net profit | EUR 558K | — |
| Total assets | — | — |
| Equity | EUR 9M | +7% |
| Employees | 12 | — |
Legal name
Biogen Finland Oy
Y-tunnus number
1538877-3
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
24. toukokuuta 1999
Share capital
EUR 8 409
Employees
12 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen jäsen yksin
Company purpose
Föremålet för bolagets verksamhet är marknadsföring, försäljning och distribution av läkemedel samt annan därmed tillhörig verksamhet.
Address
Bertel Jungin Aukio 5-C
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 13 782 | 18 754 | 20 510 | 18 550 | 19 046 |
| Staff expenses | −2 815 | −3 310 | −3 050 | −3 325 | −1 806 |
| EBITDA | 778 | 956 | 769 | 0 | 703 |
| Depreciation & amort. | −33 | −65 | −54 | −47 | −23 |
| EBIT | 745 | 891 | 715 | 675 | 680 |
| Net financials | 12 | 13 | 7 | 0 | 17 |
| Profit before tax | 758 | 904 | 722 | 0 | 698 |
| Tax | 236 | 182 | 152 | −0 | −0 |
| Net profit | 522 | 722 | 570 | 0 | 558 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 892 | 10 297 | 9 832 | 0 | — |
| Equity | 6 582 | 7 304 | 7 874 | 8 416 | 8 974 |
| Long-term debt | 192 | 354 | 327 | 0 | — |
| Short-term debt | 2 118 | 2 639 | 1 632 | 0 | — |
| Total debt | 2 310 | 2 993 | 1 958 | 0 | — |
EBITDA margin
3.7%
This company
15.8%
Market median
-77% vs market
20202024
Equity ratio
897421100.0%
This company
38.2%
Market median
+2349269795% vs market
20202024
Return on equity
6.2%
This company
18.4%
Market median
-66% vs market
20202024
Net profit margin
2.9%
This company
8.1%
Market median
-64% vs market
20202024
Asset turnover
19046272.00×
This company
1.12×
Market median
+1700559900% vs market
20202024
Debt / equity
-1.00×
This company
0.62×
Market median
+261% vs market
20202024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TK Person with significant control | Person with significant control | 2024 |
ML Chief Executive Officer | Chief Executive Officer | 2024 |
ME Person with significant control | Person with significant control | 2018 |
| Former (4) | ||
JS Person with significant control | Person with significant control | 2018 – 2024 |
MJ Chief Executive Officer | Chief Executive Officer | 2017 – 2024 |
TH | Audit | 2015 – 2023 |
JE Person with significant control | Person with significant control | 2018 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2017 | |
| Former (2) | ||
| Board of Directors | 2017 – 2022 | |
| Board of Directors | 2017 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biogen Finland Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jann Saxtorph Haagaard | Person with significant control | 0 companies |
| Mikko Juhani Fernström | Chief Executive Officer | 0 companies |
| Tomasz Klimczak | Person with significant control | 0 companies |
| Tom Hans Henrik Kullberg | Audit | 0 companies |
| Jozef Emilius Kuiper | Person with significant control | 0 companies |
| Morten Lofthus Tangnes | Chief Executive Officer | 0 companies |
| Michael Edward Dambach | Person with significant control | 0 companies |
| Ulf Johan Ström | Board of Directors | 0 companies |
| Sérgio Ferreira Da Silva Teixeira | Board of Directors | 0 companies |
| Allan Frank Fischer Petersen | Board of Directors | 0 companies |
| Dennis Dewy Baars | Board of Directors | 0 companies |